Globin Solutions is developing a fast-acting antidote for carbon monoxide poisoning. Founded by University of Pittsburgh scientists Mark T. Gladwin, Jason J. Rose and Jesús Tejero Bravo, the company uses engineered neuroglobin designed to bind and remove carbon monoxide from blood. [1] [2]
Its preclinical program builds on animal research and aims to create a medicine that could complement oxygen-based care. More than $5 million in Series A financing and an NIH Fast-Track STTR award of up to $1.75 million have supported the company’s development work with Pitt. [3] [4] [5]